Skip to Main Content

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation S2)

Conditions

Diseases of the Nervous System | Alzheimer's Disease

Phase II-III

What is the purpose of this trial?

Brief Summary:

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

  • Trial with
    Novartis Pharmaceuticals
  • Start Date
    03/22/2018
  • End Date
    07/29/2024
Trial Image

For more information about this study, contact:

Carol Gunnoud

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/23/2018
  • Study HIC
    #2000021334